Ambitious growth
Shifting from marketing partner to developer of niche proprietary products.
Product Pipeline
From Connecting Opportunities to Creating Value together
The next phase of TriXion is about building deeper, long-term partnerships across the pharmaceutical value chain. By combining our market intelligence and commercial expertise with the R&D and manufacturing capabilities of our partners, we aim to selectively develop and bring forward niche, differentiated products — creating sustainable value for all stakeholders.
Pipeline products
Product Offering
A curated portfolio of differentiated pharmaceutical products spanning sleep medicine, hematology, oncology, cardiology, gastroenterology and more.
| Product | Therapeutic Area | Dosage | Strength | Brief Description |
|---|---|---|---|---|
| Melatonin | Sleep Medicine | Capsule | 2 mg, 3 mg and 5 mg | Oral melatonin formulation supporting healthy sleep patterns. |
| Melatonin Dual Release | Sleep Medicine | Dual-Release Tablets | 2 mg | Dual-release formulation supporting sleep initiation and maintenance. |
| Ferric Derisomaltose | Hematology / Iron Deficiency | Injection / Infusion | 100 mg/mL | IV iron therapy for iron deficiency and anemia. |
| Abiraterone Acetate | Oncology | Oral Solution | 250 mg/5 mL | Oral androgen biosynthesis inhibitor for prostate cancer. |
| Carbidopa + Levodopa | Neurology | Tablet | Multiple strengths | Established combination therapy for Parkinson’s disease. |
| Eltrombopag | Hematology | Tablet | 25 mg, 50 mg, 75 mg | Oral therapy to stimulate platelet production. |
| Famotidine | Gastroenterology | Tablet | 20 mg, 40 mg | H2-receptor antagonist for acid-related disorders. |
| Finerenone | Cardiorenal | Tablet | 10 mg, 20 mg | Non-steroidal MRA for cardiorenal disease management. |
| Mefenamic Acid | Pain Management / NSAID | Tablet | 250 mg, 500 mg | NSAID for pain and inflammatory conditions. |
| Telmisartan + Amlodipine | Cardiovascular | Tablet | 40/5 mg, 40/10 mg, 80/5 mg, 80/10 mg | Fixed-dose combination for effective blood-pressure control. |
| Tofacitinib | Rheumatology / Immunology | Tablet | 5 mg, 10 mg | JAK inhibitor for selected inflammatory disorders. |
| Tolvaptan | Nephrology / Cardiovascular | Tablet | 15 mg, 30 mg, 45 mg, 60 mg, 90 mg | V2-receptor antagonist for hyponatremia and ADPKD. |
| Vonoprazan | Gastroenterology | Tablet | 10 mg, 20 mg | P-CAB providing potent and sustained acid suppression. |
End-to-end control
Owning development, manufacturing and commercialisation for a faster response to market need.
Global reach
Delivering proprietary solutions across major and emerging markets.
Partnering and in-licensing enquiries
We welcome discussions on co-development, licensing and market-specific commercialisation of pipeline candidates.